Article
Immunology
Carson R. Reynolds, Son Tran, Mohit Jain, Aru Narendran
Summary: Neoantigen-based immunotherapeutic approaches have become an effective and highly tolerable therapeutic option in the rapidly evolving field of cancer treatment.
Article
Biology
Sara Feola, Jacopo Chiaro, Beatriz Martins, Salvatore Russo, Manlio Fusciello, Erkko Yloesmaeki, Chiara Bonini, Eliana Ruggiero, Firas Hamdan, Michaela Feodoroff, Gabriella Antignani, Tapani Viitala, Sari Pesonen, Mikaela Groenholm, Rui M. M. Branca, Janne Lehtioe, Vincenzo Cerullo, Ping-Chih Ho
Summary: We describe a streamlined pipeline for generating personalized cancer vaccines, starting from the isolation and selection of immunogenic peptide candidates expressed on tumor cells. The pipeline was validated in a mouse colon tumor model, confirming its feasibility and control of tumor lesions.
Review
Oncology
Mansi Saxena, Sjoerd H. van der Burg, Cornelis J. M. Melief, Nina Bhardwaj
Summary: Therapeutic cancer vaccines aim to induce tumor regression, eradicate minimal residual disease, establish lasting anti-tumor memory, and avoid non-specific or adverse reactions. However, challenges arise due to tumor-induced immunosuppression and immunoresistance, hindering the achievement of these goals.
NATURE REVIEWS CANCER
(2021)
Review
Oncology
Jessica Jou, Kevin J. Harrington, Mai-Britt Zocca, Eva Ehrnrooth, Ezra E. W. Cohen
Summary: Therapeutic cancer vaccines aim to create and enhance tumor-specific T-cell responses, but face challenges in achieving success. Researchers are exploring various strategies to overcome immunosuppressive mechanisms in the tumor microenvironment, improve vaccine delivery platforms, and utilize combination therapies.
CLINICAL CANCER RESEARCH
(2021)
Review
Biotechnology & Applied Microbiology
Franziska Lang, Barbara Schroers, Martin Loewer, Oezlem Tuereci, Ugur Sahin
Summary: This Review discusses the use of tumor-specific neoantigens in anticancer vaccines and introduces the mechanisms of neoantigen T cell recognition, as well as computational approaches to predict which neoantigens might confer proficient antitumor immunity in patients. Individualized treatment approaches are required to harness the full potential of the unique cancer mutations in each patient. Computational algorithms and machine-learning tools can be used to identify mutations, prioritize T cell-recognized antigens, and design personalized vaccines for each patient.
NATURE REVIEWS DRUG DISCOVERY
(2022)
Review
Biotechnology & Applied Microbiology
Richard Strasser
Summary: Protein glycosylation has a significant impact on biological processes. The type of glycan on a recombinant glycoprotein depends on protein features and cell glycosylation capabilities. Glycoengineering approaches are used to achieve specific glycan modifications, allowing for structure-function studies and optimization of therapeutic proteins.
BIOTECHNOLOGY ADVANCES
(2023)
Review
Immunology
Ditte Rahbaek Boilesen, Karen Norgaard Nielsen, Peter Johannes Holst
Summary: HPV infection is the leading cause of cervical and head and neck cancers globally, with vaccines and screening programs proving effective in prevention. However, cervical cancer remains a significant cause of morbidity and mortality, especially in developing countries. Therefore, the development of more effective therapeutic vaccines is crucial in combating HPV-related cancers.
Article
Chemistry, Multidisciplinary
Yiran Zheng, Zhiyuan Zhong
Summary: Cancer vaccines have become powerful and clinically viable therapeutic modalities for reducing tumor burden, eradicating residual cancer cells, and preventing relapse. Recent years have seen rapid advancements in next-generation cancer vaccines, with cutting-edge technologies focused on eliciting robust and durable immune responses specific to cancer, as well as reducing systemic side effects. This perspective highlights innovative strategies such as high-throughput screening for neoantigens and optimal delivery systems, knowledge-based de novo design of effective delivery platforms with tissue-targeting specificity, and synergizing cancer vaccines with clinical immunotherapeutic practices like CAR-T and anti-PD-1 therapies.
JOURNAL OF CONTROLLED RELEASE
(2022)
Review
Oncology
Chiara Corti, Pier P. M. B. Giachetti, Alexander M. M. Eggermont, Suzette Delaloge, Giuseppe Curigliano
Summary: The use of the immune system as a weapon against cancer, particularly through immune checkpoint inhibitors (ICIs), has revolutionized cancer treatment. However, the effectiveness of ICIs in treating breast cancer (BC) is limited, except for certain subsets of triple-negative BCs. The tumor microenvironment (TME), which is immune-suppressive in BC, plays a crucial role in the poor response to immunotherapy. Cancer vaccines (CVs), as active immunotherapy, have regained attention due to technological advancements and the COVID-19 pandemic, with a focus on neoantigens as preferred targets. Lipid nanoparticles have also shown promise as effective delivery vehicles for CVs. Past clinical trials mainly focused on metastatic disease, where the TME is more likely compromised by inhibitory mechanisms. Promising strategies include using CVs as monotherapy in premalignant or adjuvant settings, and combining CVs with ICIs in late-stage disease. This review provides a comprehensive overview of the current landscape of breast cancer vaccines.
EUROPEAN JOURNAL OF CANCER
(2022)
Review
Oncology
Lianru Zhang, Xipeng Zhou, Huizi Sha, Li Xie, Baorui Liu
Summary: Breast cancer is the most common malignancy worldwide, and advanced breast cancer remains incurable due to its heterogeneity and limited immunogenicity. The success of cancer immunotherapy has opened up new possibilities for breast cancer treatment, with therapeutic cancer vaccines being a significant area of research. Personalized vaccines, tumor-associated antigens, and tumor-specific antigens are all targets in vaccine development. Recent technological advancements have made personalized vaccination for breast cancer possible.
FRONTIERS IN ONCOLOGY
(2022)
Review
Genetics & Heredity
Jose Alexandre Ferreira, Marta Relvas-Santos, Andreia Peixoto, Andre M. N. Silva, Lucio Lara Santos
Summary: Molecular-assisted precision oncology, supported by high-throughput sequencing and bioinformatics, has laid the foundation for genomics-based cancer medicine, but the low mutational burden of many lesions poses challenges to generalizing solutions, requiring a diversification of new antigen sources. Customized protein annotation databases for mass spectrometry to explore protein forms generated by post-translational modifications are crucial. Researchers envision that this concept may generate novel paradigms for precision oncology and immunotherapy.
GENOMICS PROTEOMICS & BIOINFORMATICS
(2021)
Editorial Material
Immunology
Camila Robles-Oteiza, Catherine J. Wu
Summary: Lessons learned from the rapid deployment of vaccines during the COVID-19 pandemic are reinvigorating the cancer vaccine field, with recent clinical trials demonstrating the safety and feasibility of cancer vaccines using delivery platforms such as mRNA and synthetic long peptides. However, fundamental questions remain regarding the optimal delivery platforms and antigen targets to use in cancer vaccines.
CURRENT OPINION IN IMMUNOLOGY
(2022)
Review
Biochemistry & Molecular Biology
Ting Fan, Mingna Zhang, Jingxian Yang, Zhounan Zhu, Wanlu Cao, Chunyan Dong
Summary: With the development and regulatory approval of immune checkpoint inhibitors and adoptive cell therapies, cancer immunotherapy has undergone a profound transformation over the past decades. Recently, therapeutic cancer vaccines have shown promise by eliciting de novo T cell responses targeting tumor antigens. However, current clinical attempts toward developing cancer vaccines have not yielded breakthrough clinical outcomes due to significant challenges.
SIGNAL TRANSDUCTION AND TARGETED THERAPY
(2023)
Article
Engineering, Biomedical
Dixita Ishani Viswanath, Hsuan-Chen Liu, David P. Huston, Corrine Ying Xuan Chua, Alessandro Grattoni
Summary: Landmark successes in oncoimmunology have led to the development of cancer vaccines using biomaterials to enhance the host immune system against tumors. This review focuses on strategies to attract dendritic cells, activate them against tumor-specific antigens, and stimulate T cells in secondary lymphoid organs. Personalized cancer vaccines have the potential to generate long-term systemic immunity against patient- and tumor-specific antigens.
Review
Oncology
Shou-En Wu, Yi-Hsien Chen, Chih-Tsung Hung, Bing-Heng Yang
Summary: The development of immunotherapies for nonmelanoma skin cancer (NMSC) has been slower compared to melanoma due to the curability of most NMSC cases through surgery. However, with the increasing incidence rate and the presence of unresectable or advanced-stage tumors, the demand for systemic therapy is rising. The use of immunotherapeutic strategies such as immune checkpoint inhibitors and T-cell therapy has shown satisfactory results in some patients but not all, with accompanying adverse events causing noncompliance. Therapeutic cancer vaccines, which prime T cells to attack tumors, have emerged as a potential approach with ongoing clinical trials in NMSCs.
CURRENT TREATMENT OPTIONS IN ONCOLOGY
(2023)
Article
Immunology
Shravan Madireddi, So-Young Eun, Amit K. Mehta, Aruna Birta, Dirk M. Zajonc, Toshiro Niki, Mitsuomi Hirashima, Eckhard R. Podack, Taylor H. Schreiber, Michael Croft
JOURNAL OF IMMUNOLOGY
(2017)
Meeting Abstract
Immunology
Rajesh Sharma, Rich-Henry Schabowsky, Abhishek Srivastava, Esma Yolcu, Kutlu Elpek, Hong Zhao, Shravan Madireddi, Haval Shirwan
CLINICAL IMMUNOLOGY
(2010)
Article
Immunology
Shravan Madireddi, So-Young Eun, Seung-Woo Lee, Ivana Nemcovicova, Amit Kumar Mehta, Dirk M. Zajonc, Nozomu Nishi, Toshiro Niki, Mitsuomi Hirashima, Michael Croft
JOURNAL OF EXPERIMENTAL MEDICINE
(2014)
Article
Immunology
Seung-Woo Lee, Yunji Park, So-Young Eun, Shravan Madireddi, Hilde Cheroutre, Michael Croft
JOURNAL OF IMMUNOLOGY
(2012)
Article
Multidisciplinary Sciences
Shravan Madireddi, Rich-Henry Schabowsky, Abhishek K. Srivastava, Rajesh K. Sharma, Esma S. Yolcu, Haval Shirwan
Review
Immunology
Michael Croft, Wei Duan, Heonsik Choi, So-Young Eun, Shravan Madireddi, Amit Mehta
TRENDS IN IMMUNOLOGY
(2012)
Article
Immunology
Rich-Henry Schabowsky, Kutlu G. Elpek, Shravan Madireddi, Rajesh K. Sharma, Esma S. Yolcu, Laura Bandura-Morgan, Robert Miller, Kathryn J. MacLeod, Robert S. Mittler, Haval Shirwan
Article
Immunology
Rajesh K. Sharma, Abhishek K. Srivastava, Esma S. Yolcu, Kathryn J. MacLeod, Rich-Henry Schabowsky, Shravan Madireddi, Haval Shirwan
Article
Medicine, Research & Experimental
Yanli Yang, Sherry H. Yeh, Shravan Madireddi, Wadim L. Matochko, Chen Gu, Patricia Pacheco Sanchez, Mark Ultsch, Gladys De Leon Boenig, Seth F. Harris, Brandon Leonard, Suzie J. Scales, Jing W. Zhu, Erin Christensen, Julie Q. Hang, Randall J. Brezski, Scot Marsters, Avi Ashkenazi, Siddharth Sukumaran, Henry Chiu, Rafael Cubas, Jeong M. Kim, Greg A. Lazar
Article
Multidisciplinary Sciences
Thomas D. Wu, Shravan Madireddi, Patricia E. de Almeida, Romain Banchereau, Ying-Jiun J. Chen, Avantika S. Chitre, Eugene Y. Chiang, Hina Iftikhar, William E. O'Gorman, Amelia Au-Yeung, Chikara Takahashi, Leonard D. Goldstein, Chungkee Poon, Shilpa Keerthivasan, Denise E. de Almeida Nagata, Xiangnan Du, Hyang-Mi Lee, Karl L. Banta, Sanjeev Mariathasan, Meghna Das Thakur, Mahrukh A. Huseni, Marcus Ballinger, Ivette Estay, Patrick Caplazi, Zora Modrusan, Lelia Delamarre, Ira Mellman, Richard Bourgon, Jane L. Grogan
Article
Biochemistry & Molecular Biology
Kobe C. Yuen, Li-Fen Liu, Vinita Gupta, Shravan Madireddi, Shilpa Keerthivasan, Congfen Li, Deepali Rishipathak, Patrick Williams, Edward E. Kadel, Hartmut Koeppen, Ying-Jiun Chen, Zora Modrusan, Jane L. Grogan, Romain Banchereau, Ning Leng, AnnChristine Thastrom, Xiadong Shen, Kenji Hashimoto, Darren Tayama, Michiel S. van der Heijden, Jonathan E. Rosenberg, David F. McDermott, Thomas Powles, Priti S. Hegde, Mahrukh A. Huseni, Sanjeev Mariathasan
Article
Biochemical Research Methods
Jieming Chen, Shravan Madireddi, Deepti Nagarkar, Maciej Migdal, Jason Vander Heiden, Diana Chang, Kiran Mukhyala, Suresh Selvaraj, Edward E. Kadel, Matthew J. Brauer, Sanjeev Mariathasan, Julie Hunkapiller, Suchit Jhunjhunwala, Matthew L. Albert, Christian Hammer
Summary: Immunogenetic variation in humans is crucial for research and clinical diagnosis, with the HLA system and KIR receptors playing critical roles. Recent algorithm evaluations show promising accuracy in computationally inferring HLA alleles and KIR haplotypes, indicating their potential use in clinical and high-throughput research settings.
BRIEFINGS IN BIOINFORMATICS
(2021)
Article
Oncology
Romain Banchereau, Avantika S. Chitre, Alexis Scherl, Thomas D. Wu, Namrata S. Patil, Patricia de Almeida, Edward E. Kadel, Shravan Madireddi, Amelia Au-Yeung, Chikara Takahashi, Ying-Jiun Chen, Zora Modrusan, Jacqueline McBride, Rhea Nersesian, Ehab A. El-Gabry, Mark D. Robida, Jeffrey C. Hung, Marcin Kowanetz, Wei Zou, Mark McCleland, Patrick Caplazi, Shadi Toghi Eshgi, Hartmut Koeppen, Priti S. Hegde, Ira Mellman, W. Rodney Mathews, Thomas Powles, Sanjeev Mariathasan, Jane Grogan, William E. O'Gorman
Summary: CD8+ tissue-resident memory T (T-RM) cells expressing CD103 (ITGAE) are believed to actively suppress cancer progression, and their presence in tumors may predict response to immunotherapy. This study found that in inflamed tumors, CD103+ CD8+ T-RM cells exhibit a complex phenotype characterized by increased clonal expansion, expression of checkpoint regulators, and cytotoxic proteins, suggesting their involvement in antitumor response.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Immunology
Shilpa Keerthivasan, Yasin Senbabaoglu, Nadia Martinez-Martin, Bushra Husain, Erik Verschueren, Anne Wong, Yeqing Angela Yang, Yonglian Sun, Victoria Pham, Trent Hinkle, Yoko Oei, Shravan Madireddi, Racquel Corpuz, Lucinda Tam, Samantha Carlisle, Merone Roose-Girma, Zora Modrusan, Zhengmao Ye, James T. Koerber, Shannon J. Turley
Summary: The collagen receptor LAIR1 plays a crucial role in the homeostasis and function of myeloid cells, particularly in non-classical monocytes. LAIR1 interacts with the stromal factor Colec12 to initiate signaling pathways associated with survival, proliferation, and differentiation. LAIR1 deficiency in myeloid cells leads to altered cellular processes and promotes metastatic growth in a melanoma model, highlighting its significance in both health and disease.